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205Letter to the Editor
The use of high-dose acyclovir in patients with
hematological malignancies who develop herpes
virus infections: Is it really safe? 
Hematolojik hastal›¤› olan herpes virusu geliflen hastalarda yüksek doz asiklovir
kullan›m›. Gerçekten güvenli mi? 
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Infections with herpes viruses are a common phenomenon in
patients being treated for hematological malignancies who
undergo stem cell transplantation (SCT). The safe use of high-
dose acyclovir in these patients has been established in numer-
ous clinical trials [1]. Most reported adverse effects are tolerable
and generally reversible [1]. Life-threatening effects such as
severe neurotoxicity or nephrotoxicity have rarely been reported
in the documented literature [2,3]. Therefore, we hereby share
our experience regarding a patient with plasma cell leukemia
who developed severe neurotoxicity and irreversible nephrotoxi-
city due to high-dose acyclovir.
A 42-year-old female with resistant plasma cell leukemia was
admitted to our hematology unit. Type II diabetes mellitus (DM)
had been diagnosed 10 years before. EDAP chemotherapy reg-
imen was initiated in the patient and she was discharged on day
9. On day 16, she was readmitted with neutropenic fever and
herpes labialis infection. The patient’s white blood cell count and
platelet count were 2.2x109/mm3 (20% PMNL) and
22x109/mm3, respectively. Renal and hepatic function tests and
serum calcium level were normal. Urine examination revealed 3+
protein, and 3 to 5 white blood cells. At the point of hospitaliza-
tion, urine output was approximately 2300 ml/day. Cefepime (2
g intravenously every 8 hours) was initiated according to febrile
neutropenia protocol. Additionally, high-dose acyclovir (1500
mg/m2) was added to the therapy because the underlying dis-
ease was not under control. On day 3, serum creatinine levels
increased to 5.1 mg/dl and she became confused and devel-
oped periods of unconsciousness. Her blood pressure was
120/70 mmHg, with a heart rate of 98 beats per minute. Urine
output was 800 ml/day and urine sediment revealed 1 to 2 white
blood cells, and 6 to 7 white blood cells, consecutively. Urine
quantitative analysis of the patient revealed osmolarity of 270
mOsm, urinary sodium of 70 mEq/L, fractional excretion of sodi-
um of >1% and proteinuria of 2.1 g/dl.
On the same day, a cranial tomographic scan ruled out cere-
bral tumor and hemorrhage. The cerebrospinal fluid had a mild-
ly elevated protein level (0.50 g/L), but no malignant cells were
found. In addition, bacterial and viral cultures were negative, and
an electroencephalogram showed diffuse slowing and no
seizure activity. Serum electrolytes, glucose, and acid-base sta-
tus were normal. On day 5, we discontinued the use of acyclovir
upon consideration of the adverse effects of acyclovir-induced
consciousness disturbances and acute renal failure.
Two days later, a clinical improvement was seen in her level
of consciousness. She was able to respond to pain and open
her eyes spontaneously. On day 12, she became increasingly
alert, could answer questions appropriately, and began to walk.
Further, four days after the discontinuation of acyclovir, urine
output increased to 3400 ml/day, and serum creatinine level
decreased to 3.2 mg/dl. Creatinine levels did not return to nor-
mal but remained constant for subsequent days, although high
urine output was observed. She was discharged and recom-
mended as a recipient for allogeneic SCT.
Acyclovir neurotoxicity is a self-limiting, dose-dependent,
rare phenomenon that is more likely to occur in elderly patients.
It is distinguished from viral encephalitis by its sudden onset,
absence of fever or headache, lack of focal neurological findings
and normal cerebrospinal fluid [4]. It should be emphasized that
patients with acyclovir neurotoxicity may not have renal insuffi-
ciency before receiving acyclovir, as was the case with our
patient. The most common manifestations of acyclovir neurotox-
icity are confusion, delirium, hallucinations, lethargy, and mild
tremors. The neurological status of our patient with resolution of
symptoms within approximately one week of acyclovir withdraw-
al is in agreement with other reports on acyclovir toxicity [5].
Acyclovir-induced nephrotoxicity is well known and is also
uncommon, like its neurotoxicity. Furthermore, it is more com-
mon in patients treated with high- dose cytotoxic chemotherapy
than in other patient populations treated with acyclovir. Acute
renal failure mediated by this compound is characterized by
abrupt elevations in serum creatinine and a gradual return to
baseline renal function upon discontinuation of the drug. Since
our patient had DM type 2, and proteinuria was determined in
her routine examination before chemotherapy, DM with protein-
uria might have predisposed her to irreversible renal function
abnormalities in the presence of acyclovir. When such patients
with subclinical renal disorders have elevated serum creatinine
levels in conjunction with acyclovir therapy, the acyclovir should
be considered as a potential cause. Additionally, acyclovir,
cefepime, and also cisplatin, which were used in the chemother-
apy regimen, are eliminated by both glomerular filtration and
tubular secretion. It is possible that the interaction of these drugs
partly contributed to the tubular damage [6].
Due to our report lacking a renal biopsy, we were unable to
document any pathological changes. We could not perform
renal biopsy because of the low performance status of the
patient. Additionally, our report did not include a record of serum
acyclovir levels. However, measurement of acyclovir levels is not
practical or useful for the diagnosis of acyclovir neurotoxicity
because the assay is not widely available and the delay imposed
by handling specimens and receiving results reduces the test’s
utility [7]. 
In conclusion, severe acute renal failure and neurotoxicity
may be associated with intravenous acyclovir. This case sug-
gests that patients being treated by standard or high-dose
chemotherapy with subclinical renal abnormalities (e.g. history of
DM, proteinuria or nephrotoxic drugs) may be at an increased
risk and should be monitored closely for signs and symptoms of
acute renal failure and neurotoxicity while receiving acyclovir.
Physicians involved with high-dose chemotherapy and SCT
must be alert to other potentially toxic medications that are being
used for the primary disease or other disease-related problems.
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